• Who We Are
    • About Us
    • Leadership
    • Member Partners
    • International Advisory Board
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • About the Issue
    • FAQs
    • Naming
    • Substitution Policy
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • European Union
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos

Safe Biologics

  • Safe Biologics

  • Who We Are
    • About Us
    • Leadership
    • Member Partners
    • International Advisory Board
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • About the Issue
    • FAQs
    • Naming
    • Substitution Policy
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • European Union
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos
323915183

Substitution Policy

Backgrounders


Backgrounder: Interchangeability and Substitution
Backgrounder: Indication Extrapolation

In the States

Latest News

GaBI Journal Publishes ASBM/IFA Canadian Ophthalmologist Survey Findings

On May 9th, GaBI Journal published a whitepaper titled “Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars”, based on the recent survey of 41 Canadian ophthalmologists by ASBM and the International Federation on Ageing (IFA). The paper is authored by IFA Secretary-General Jane Barratt and ASBM Executive Director Michael Reilly. The survey revealed that 81% were not […]

Read More

GaBI Journal publishes Meeting Report on ASBM Non-Medical Switching Webinar

On April 30th, the Generics and Biosimilar Initiative (GaBI) published a meeting report on a 2-hour webinar entitled “Non-Medical Switching of Biologicals and Biosimilars: Canada, Europe, and the US”, hosted July 20th, 2022 by ASBM and GaBI. During the webinar, academic clinicians, patient advocates, policymakers and regulatory experts from Canada and the US shared their experience and […]

Read More

ASBM’s Comments on the Medicare Drug Price Negotiation Plan: Protecting Patients and Ensuring Access to Medicines

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. Under this plan – authorized by the Inflation Reduction Act (IRA) signed in to law last year – Medicare will “negotiate” (set) maximum […]

Read More

logo logo logo
logo

The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups — from patients to physicians, medical innovators, and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion.

Contact Us

Who we are
  • About Us
  • Leadership
  • Member Partners
  • International Advisory Board
News
  • Latest News
  • Letters
  • Newsletter
  • Press Releases
  • Recent Events
The Issue
  • About the Issue
  • FAQs
  • Naming
  • Substitution Policy
  • Biologic Safety
  • BIO Principles
Policy
  • Australia
  • Canada
  • European Union
  • FDA
  • FDA Guidance
  • In the States
Resources
  • Surveys
  • Courses
  • Webinars